Filing summary
Entity mismatch: The request identifies Cibus, Inc., but the supplied Form 10-Q is for Calyxt, Inc. (NASDAQ: CLXT). The summary below reflects Calyxt’s filing, not Cibus’s.
Business context and reporting period
Quarter ended June 30, 2021; filed August 5, 2021. Calyxt is a plant-based biotechnology company developing and commercializing products derived from plant cells. Its commercial activity included high-oleic soybean grain and seed sales. Cellectis owned 64.4% of Calyxt’s outstanding common stock at June 30, 2021.
Key financial metrics
| Metric | Q2 2021 | First six months 2021 |
|---|---|---|
| Revenue | $11.9 million | $16.3 million |
| Gross margin | $0.4 million (3%) | $(2.0) million (-12%) |
| Operating expenses | $6.3 million | $13.7 million |
| Net loss | $(4.8) million | $(14.8) million |
| Net loss per share | $(0.13) | $(0.40) |
| Adjusted EBITDA loss | $(5.8) million | $(12.6) million |
| Cash used by operating activities | Not stated for quarter | $(11.2) million |
At June 30, cash and cash equivalents were $17.5 million; cash, cash equivalents, and restricted cash totaled $18.5 million, with no short-term investments. Current liabilities were $7.2 million. Total financing lease obligations were approximately $18.1 million; the $1.5 million PPP loan was forgiven, leaving no long-term debt reported. Total assets were $47.8 million and stockholders’ equity was $21.9 million.
Material changes versus comparable periods
Q2 revenue rose 415% year over year, primarily from selling seed and 25% of the 2020 grain crop, rather than soybean oil and meal in Q2 2020. First-half revenue increased 248%. Q2 gross margin improved from a $3.0 million loss to $0.4 million; first-half gross margin improved from a $4.5 million loss to a $2.0 million loss. The company attributed improvement partly to the shift to grain sales, lower inventory write-downs, and derivative impacts; adjusted gross margin remained negative in both periods.
Q2 net loss narrowed by $6.1 million year over year, and first-half net loss narrowed by $7.1 million. Lower SG&A contributed, including reduced personnel and stock-compensation costs; first-half SG&A also reflected a $2.7 million officer-transition expense and a $2.5 million stock-compensation recapture. First-half operating cash use improved by $14.4 million year over year, principally due to working-capital changes and lower net loss. Cash balances were supported in part by liquidation of short-term investments.
Outlook, commentary, risks, and unusual items
Management said existing cash, expected grain-sale receipts, licensing and development efforts, and expense reductions were expected to fund operations for at least 12 months and into the second half of 2022. It expects losses for several years and anticipates lower operating cash use in the second half of 2021 than in the second half of 2020. No earnings or revenue guidance was provided.
The strategy is shifting toward product development and licensing, with anticipated upfront, milestone, annual license, and royalty revenue; management expects such revenue to have higher margins over time. The filing listed target commercial planting years for disclosed products, including alfalfa in 2022, wheat and certain soybean and hemp products in 2023–2024, and oats and high-saturated-fat soybean in 2026. These timelines and product outcomes remain subject to development risks and partner arrangements.
Notable items include the $1.5 million gain from PPP loan forgiveness and $2.2 million of remaining severance obligations, primarily related to former CEO James Blome. Michael A. Carr was appointed CEO effective July 27, 2021, after the quarter. The company reported no material pending legal proceedings and no material changes to its previously disclosed risk factors. Risks include continuing losses and possible need for additional financing, which may be unavailable or dilutive; commodity-price and grain-sale exposure; product development, regulatory, partner, and commercialization uncertainty; and possible COVID-19 or supply-chain disruption. Management reported disclosure controls were effective.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Calyxt, Inc. (CLXT), not Cibus, Inc.
- Track completion and cash collection from the remaining 2020 grain crop, and whether grain sales generate sustainable margins.
- Assess the assumptions supporting management’s stated cash runway into the second half of 2022, given ongoing losses and financing risk.
- Review commodity derivative and inventory adjustments, and compare GAAP results with the company’s non-GAAP measures.
- Monitor licensing partners, product development progress, and the stated commercial planting targets.
- Consider potential dilution from equity financing and outstanding equity awards, as well as Cellectis’s majority ownership.